المؤلفون: O. A. Dorofeeva, M. V. Metlina, S. A. Siuniakov, G. G. Neznamov

المصدر: Качественная клиническая практика, Vol 0, Iss 2, Pp 57-63 (2018)

مصطلحات موضوعية: тревожные расстройства, качество жизни, анксиолитическое средство, афобазол, клинико-фармакологическое исследование, anxiety disorders, quality of life, anxiolytic, fabomotizole, clinical and pharmacological research, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

الوصف: The results of the quality of life (QoL) changes study during fabomotizole treatment in patients with anxiety disorders are presented. The QoL indexes measured with WHOQOL-BREF questionnaire in patients with anxiety disorders are significantly decreased compared to healthy persons. Fabomotizole treatment is associated with both positive changes in QoL and anxiety symptoms reduction. Given the need to treat anxiety disorders in outpatient settings and importance to maintain patient’s optimal social performance and QoL it is reasonable to use fabomotizole as the first line treatment.

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/48; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/edc35991eb4342ebbab107373e4186c9

المؤلفون: G. G. Neznamov, E. S. Teleshova

المصدر: Neuroscience and behavioral physiology. 39(3)

مصطلحات موضوعية: Adult, Brain Diseases, Time Factors, Adolescent, General Neuroscience, Behavioural sciences, Piracetam, Cognition, Dipeptides, Middle Aged, Neuroprotective Agents, Treatment Outcome, Brain Injuries, medicine, Humans, Psychology, Cognition Disorders, Nootropic Agents, Noopept, medicine.drug, Clinical psychology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b615939f7c89151f1ec59ef6e6c8bee9
https://pubmed.ncbi.nlm.nih.gov/19234797

المؤلفون: T S Syunyakov, G G Neznamov

المصدر: Терапевтический архив, Vol 88, Iss 8, Pp 73-86 (2016)

مصطلحات موضوعية: anxiolytics, afobazole, fabomotizole, diazepam, generalized anxiety disorder, adjustment disorder, randomized clinical trial, Medicine

الوصف: Aim. To summarize the previously published results of a multicenter randomized clinical research phase III study trial of afobazole (INN: fabomotizole) versus diazepam in the treatment of patients with generalized anxiety disorder (GAD) and adjustment disorders (AD). Subjects and methods. Five investigating centers included 150 patients aged 18 to 60 years (60 patients with GAD and 90 with AD) a simple structure of anxiety disorders without concurrent mental, neurological or somatic disorders. Patients were randomized to take afobazole (30 mg/day; n=100) or diazepam (30 mg/day; n=50) for 30 days. Prior to drug administration, patients susceptible to placebo were excluded according to the results of its 7-day use. Withdrawal syndrome was evaluated within 10 days after completion of active therapy. The primary efficacy endpoint was the change of Hamilton Anxiety Rating Scale (HAMA) total score. The scores of the Clinical Global Impression (CGI) Scale and the Sheehan Scale as secondary efficacy endpoints were analyzed. Drug safety was evaluated by assessment of adverse events. Results. Afobazole and diazepam caused a significant reduction of HAMA total score. In the afobazole group, the reduction of anxiety exceeded that in the diazepam group (the difference in the total score changes was 2.93 [0.67; 5.19]; p=0,01).The proportion of patients with reduction of disease severity was 72% in the afobazole group and 58% in the diazepam group. After therapy completion, the proportion of patients with no or mild disorder in the afobazole group was significantly higher than that in the diazepam group (69 and 44%, respectively; χ2=12.46; p=0,014). There was a trend toward a higher subjective patient-rated estimate of the afobazole effect using the Sheehan scale. There were a total of 15 and 199 adverse events in the afobazole and diazepam groups, respectively. No manifestations of afobazole withdrawal syndrome were found. Diazepam withdrawal syndrome was observed in 34 (68%) patients. Conclusion. Afobazole is an effective and safe drug to treat patients with GAD and AD and non-inferior than diazepam in the treatment of these disorders, however it is superior in terms of several variables, including the safety profile.

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/viewFile/32088/pdf; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/d5661be1ff394084a6e67f0b8d7bc4e5